UK markets close in 7 hours 46 minutes

ArriVent BioPharma, Inc. (AVBP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
16.80+0.11 (+0.66%)
At close: 04:00PM EDT
16.80 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close16.69
Open16.99
Bid16.69 x 100
Ask16.90 x 200
Day's range16.54 - 17.39
52-week range14.35 - 25.95
Volume60,848
Avg. volume188,881
Market cap562.696M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est30.20
  • GlobeNewswire

    ArriVent Appoints Kristine Peterson to its Board of Directors

    NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta Pharmaceuticals. “We are thrilled for Kris to join our Boa

  • GlobeNewswire

    ArriVent BioPharma Reports Full Year 2023 Financial Results

    Company progresses the development of furmonertinib with a data readout planned for 2024Furmonertinib granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration Completed $201 million initial public offering (“IPO”) in January 2024 NEWTOWN SQUARE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, to